Skip to main content

Life Sciences is now live. See how →

Patent Examiner Jacob A. Boeckelman

Art Unit 1655 · Plant, Fungal & Animal-Derived Extracts · Tech Center 1600 · 266 applications filed 2021–2026

⚑ Extremely Hard · harder than 94% of examiners● Free examiner data

Jacob A. Boeckelman is a USPTO patent examiner in Art Unit 1655 (Plant, Fungal & Animal-Derived Extracts) with 266 applications from filing years 2021–2026. Examiner Boeckelman's allowance rate is 36.7%, below the 81.5% USPTO average for applications filed in the same years. The examiner ranks harder than 94% of examiners. In 2021, decided applications with an examiner interview were allowed 62.2 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Extremely Hard
harder than 94% of examiners
Easier94th percentileHarder
Allowance rate vs peers
Examiner Boeckelman36.7%
Art Unit 165562.8%
USPTO average81.5%
Allowance rate
36.7%
▼ USPTO avg 81.5%
Applications
266
filing years 2021–2026
First-action allowance
4.3%
patented with no rejection
Abandoned
33.1%
share of applications
Avg office actions
1.8
USPTO avg 1.3
Days to first OA
758
▲ USPTO 624
RCE rate
29.7%
USPTO 20.2%
Interview rate
22.2%
USPTO 27.9%

Examiner details

  • Art unit1655 · Plant, Fungal & Animal-Derived Extracts
  • Title / gradePatent Examiner · GS-13
  • Service6 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsBOECKELMAN, JACOB A
Examines (USPC classes)
424 · Drug, Bio-Affecting & Body Treating Compositions

How to improve your odds with Examiner Boeckelman

  • The data favors an interview. Interviewed cases were allowed more often in both measured years, by 43.1 to 62.2 points.
  • Plan for the timeline. First office action averages 758 days vs the 624-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (273), and applicants overcame it 26.8% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 29.5 to 29.9 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility76 issued · 34.7% overcome
§102 Novelty72 issued · 52.9% overcome
§103 Obviousness273 issued · 26.8% overcome
§112 Definiteness & disclosure101 issued · 52.3% overcome
How applicants traverse §103 rejections🔒 Members

Of the 19 winning responses to Examiner Boeckelman's §103 rejections that Boundly has classified, 18 (95%) amended the claims and argued, and 1 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Boeckelman?

Draft your response with Examiner Boeckelman's record and Art Unit 1655's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Boeckelman.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202238.0%61.5%31.6%+29.9pp
202134.2%55.6%26.1%+29.5pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/275643Composition Containing Black Ginseng as Active Ingredient for Prevention, Alleviation, or Treatment of Coronavirus InfectionAbandoned0🔒 View
18/278227Composition for Strengthening, Developing, Differentiating, or Regenerating Muscle, or Preventing, Ameliorating, or Treating Muscle Loss or Muscle Fatigue Comprising Schizonepeta tenuifolia Extract as Effective ComponentPatented1🔒 View
18/380875Method for Extracting and Purifying Total Flavonoids from Carthamus tinctorius L. Leaf (TFFCL), and Use ThereofAbandoned1🔒 View
17/665037Autologous Thymic Tissue TransplantationAbandoned4🔒 View
See all 266 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1655 technology

Plant & herbal extractsAnimal-derived extractsMushroom, fungal & algal extractsCosmetics & dietary supplementsTop CPC A61K · A23L · A61Q
About this examiner. Jacob A. Boeckelman examines in Art Unit 1655 (Plant, Fungal & Animal-Derived Extracts, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Jacob A. Boeckelman's allowance rate?
Examiner Boeckelman's allowance rate is 36.7%, compared with 81.5% across the USPTO and 62.8% in Art Unit 1655 for applications filed in the same years. That rate ranks Examiner Boeckelman harder than 94% of examiners.
Is Examiner Boeckelman a hard examiner?
Yes, markedly. Examiner Boeckelman ranks harder than 94% of examiners, in the 94th difficulty percentile (extremely hard). Examiner Boeckelman has a 36.7% allowance rate versus 81.5% across the USPTO and 62.8% in Art Unit 1655, 1.8 office actions per application versus 1.3, and an RCE rate of 29.7% versus 20.2% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Boeckelman?
In this examiner's record, yes. Decided applications with an interview were allowed more often in both measured years, by 43.1 to 62.2 percentage points. In 2021, 76.2% of decided applications with an interview were allowed, versus 14.0% of those without.
What is Examiner Boeckelman's most common rejection?
§103 obviousness, issued 273 times in the data. Applicants overcame it 26.8% of the time. Of the 19 winning responses Boundly has classified, 18 amended the claims and argued.
Is an RCE worth filing with Examiner Boeckelman?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in both measured years, by 29.5 to 29.9 percentage points. In 2021, 55.6% of decided applications with an RCE were allowed, versus 26.1% of those without one.
How long until the first office action from Examiner Boeckelman?
About 758 days on average, versus 624 days across the USPTO for applications filed in the same years.
How do I contact Examiner Jacob A. Boeckelman?
Examiner Boeckelman can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Boeckelman's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Jacob A. Boeckelman, or see an error? Request a correction.